What are the recommended dosing regimens for spironolactone and eplerenone based on estimated glomerular filtration rate (eGFR)?

Dosing Spironolactone and Eplerenone Based on GFR

Both spironolactone and eplerenone require GFR-based dose adjustments, with initiation contraindicated when eGFR <30 mL/min/1.73 m² and requiring dose reduction when eGFR is 30-50 mL/min/1.73 m².

Initial Dosing Algorithm by eGFR

For Heart Failure:

eGFR >50 mL/min/1.73 m²:

• Spironolactone: Start 25 mg once daily 1, 2
• Eplerenone: Start 25 mg once daily 1, 3

eGFR 30-50 mL/min/1.73 m²:

• Spironolactone: Start 12.5-25 mg once daily OR 25 mg every other day 1, 2
• Eplerenone: Start 25 mg every other day 1, 3

eGFR <30 mL/min/1.73 m²:

• Both drugs are CONTRAINDICATED 1, 3, 2

For Hypertension:

eGFR ≥50 mL/min/1.73 m²:

• Spironolactone: Start 25-100 mg once daily 2
• Eplerenone: Start 50 mg once daily 3

eGFR 30-49 mL/min/1.73 m²:

• Eplerenone: Reduce initial dose by half (25 mg once daily) 1
• Spironolactone: Use with extreme caution; consider 12.5 mg daily 4

Additional contraindications for hypertension: Eplerenone is contraindicated in hypertensive patients with CrCl <50 mL/min 3

Target Maintenance Doses

After 4 weeks, if potassium ≤5.0 mEq/L and renal function stable:

• Spironolactone: Titrate to 50 mg once daily (maximum 100 mg for heart failure) 5, 1, 5
• Eplerenone: Titrate to 50 mg once daily 5, 1, 5, 3

Critical Monitoring Requirements

Check potassium and renal function:

• At 1 week after initiation 1
• At 4 weeks after initiation 5
• At 1,2,3, and 6 months after reaching maintenance dose 5
• Every 6 months thereafter 5

Dose Adjustment for Adverse Effects

If potassium rises to 5.5-5.9 mEq/L:

• Halve the dose (e.g., 50 mg daily → 25 mg daily, or 25 mg daily → 25 mg every other day) 5, 1, 5

If potassium ≥6.0 mEq/L:

• STOP immediately and monitor closely 5, 1, 5
• Restart at 25 mg every other day only when potassium <5.5 mEq/L 1, 3

If creatinine rises to >220 μmol/L (2.5 mg/dL):

• Halve the dose 5

If creatinine rises to >310 μmol/L (3.5 mg/dL):

• STOP immediately 5

Key Clinical Pitfalls

Do NOT initiate if:

• Baseline potassium >5.0 mEq/L 1, 3, 2
• eGFR <30 mL/min/1.73 m² 1, 3, 2
• Concurrent use of strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) 3

Special populations requiring lower starting doses:

• Elderly patients: Start with 12.5 mg spironolactone 6, 4
• Patients on ACE inhibitors/ARBs: More frequent monitoring required 1, 3
• Patients with diabetes and microalbuminuria (for hypertension indication): Eplerenone is contraindicated 3

Important context: The 2013 ACC/AHA guidelines 1 provide the most explicit GFR-based dosing table, which has been incorporated into FDA labeling 3, 2. The ESC guidelines 5 focus more on creatinine thresholds but align with the eGFR-based approach. Recent evidence suggests that early eGFR dips (up to 15% decrease) are common and do not necessarily warrant discontinuation if patients remain clinically stable 7.

Regarding dose equivalence: Eplerenone requires 2-3 times higher doses than spironolactone for equivalent mineralocorticoid receptor blockade 4, 8, but the recommended target doses in heart failure are identical (50 mg daily) because they were derived from separate outcome trials (RALES for spironolactone, EPHESUS for eplerenone) 5.